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Elite controllers (EC) of human immunodeﬁciency virus type 1 (HIV-1) maintain viremia below the limit of
detection without antiretroviral treatment. Virus-speciﬁc cytotoxic CD8
 T lymphocytes are believed to play a
crucial role in viral containment, but the degree of immune imprinting and compensatory mutations in EC is
unclear. We obtained plasma gag, pol, and nef sequences from HLA-diverse subjects and found that 30 to 40%
of the predeﬁned HLA-associated polymorphic sites show evidence of immune selection pressure in EC,
compared to approximately 50% of the sites in chronic progressors. These data indicate ongoing viral repli-
cation and escape from cytotoxic T lymphocytes are present even in strictly controlled HIV-1 infection.
Human immunodeﬁciency virus type 1 (HIV-1)-infected
persons who control viremia to below the limit of detection
(50 RNA copies/ml plasma) without therapy have been
called elite controllers (EC) (3–5, 25, 28). Understanding the
mechanisms responsible for successful viral control should
contribute greatly to understanding HIV-1 pathogenesis and
vaccine development.
Current evidence supports the notion that virus-speciﬁc cy-
totoxic T lymphocytes (CTLs) play a crucial role in controlling
AIDS virus replication (1, 17, 18, 20, 27–32). Many studies
have indicated that broad Gag-speciﬁc CTL responses are as-
sociated with lower plasma viral loads and better clinical out-
comes (14, 19, 28, 33). However, viral escape from CTLs is
commonly seen in AIDS virus infection (1, 10, 15, 21, 29).
Recently, we reported that the replication capacity of chimeric
viruses encoding gag-protease derived from EC was signiﬁ-
cantly reduced, associated with distinct HLA class I alleles in
EC (26), suggesting that escape mutations from alleles en-
riched in EC diminish viral replicative ﬁtness. However, to
date, no population studies have examined the extent to which
HLA-associated mutations, indicative of CTL escape muta-
tions, are present in viruses from EC. In this study, we evalu-
ated HLA-associated mutations in HIV-1 protein sequences
(54 Gag, 41 reverse transcriptase [RT], and 39 Nef) derived
from plasma viruses from EC and compared these to se-
quences obtained from untreated chronic progressors (CP)
similarly obtained from North America (567 Gag, 392 RT, and
686 Nef) (7, 9). The median plasma viral load of CP was
120,000 (interquartile range, 42,000 to 310,000) RNA copies/
ml. These studies were guided by a comprehensive list of HLA-
associated polymorphisms in HIV-1 clade B deﬁned in a
cohort of more than 1,200 individuals by phylogenetically
informed methods (7–9, 16). Our objective was to deﬁne the
relative extent of polymorphisms in circulating plasma viruses
from EC that could be attributed to HLA class I selection
pressure, namely, putative CTL-driven mutations. Since there
is bias in the distribution of HLA class I alleles between EC
and CP (28), we report results in terms of the proportion of
HLA-associated polymorphic sites within a given individual’s
autologous HIV sequence exhibiting the predeﬁned speciﬁc
HLA-associated polymorphisms. For each subject, the total
number of predeﬁned HLA-associated polymorphic sites in
autologous viral sequences was determined and divided by the
potential number in the context of their speciﬁc HLA class I
allotype.
As shown in Fig. 1A, the proportion of putative CTL escape
sites observed in EC was substantial in the Gag, RT, and Nef
proteins (37.5%, 30.8%, and 42.1%, respectively) but still sig-
niﬁcantly lower than that observed in CP (0.375 versus 0.500
[P  0.0001], 0.308 versus 0.400 [P  0.0001], and 0.421 versus
0.533 [P  0.0001], respectively). The proportion of HLA-
associated mutations remained high in EC even after HLA-
B57 subjects were removed (Fig. 1B).
We repeated the analysis limited to HLA-associated sites
inside (within 3 amino acids [aa]) published (Los Alamos
National Database) or predicted (Epipred tool; Microsoft Re-
search) CTL epitopes. Limiting the analysis to these sites has
been used as an indication of mutations that are likely to
directly affect escape from CTLs (9, 23), as opposed to com-
pensatory mutations, which are usually observed more distant
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 from the epitope (6). In this analysis, the proportion of HLA-
associated mutations remained high in EC (Fig. 1C).
Intriguingly, signiﬁcant differences in HLA-associated poly-
morphisms between EC and CP were also evident in regions
outside of CTL epitopes in all three proteins, with even stron-
ger P values (Fig. 1D), which may suggest the presence of
fewer compensatory mutations among EC. Thus, accumulation
of compensatory mutations may also characterize disease pro-
gression (6). The high proportion of HLA-associated muta-
tions in EC was seen regardless of the Gag subprotein (p17,
p24, or p15) (Fig. 1E).
We next compared the proportion of HLA-associated poly-
morphisms present in the Gag and Nef proteins on an HLA-
allele-speciﬁc basis. RT was excluded because of the small
FIG. 1. Comparisons of the proportions of HLA-associated mutations between EC and CP. The mean and standard error of the proportion
of sites with deﬁned HLA-associated polymorphisms at which mutations were observed are shown. (A) Proportion of total HLA-associated sites
at which mutations were observed in all of the subjects. (B) Proportion of total HLA-associated sites at which mutations were observed in non-B*57
subjects. (C) Proportion of HLA-associated sites falling within predicted CTL epitopes at which mutations were observed (inside epitopes and 
3 aa) in all subjects. (D) Proportion of HLA-associated sites outside of predicted CTL epitopes (outside of predicted epitopes and 3 aa) at which
mutations were observed in all subjects. (E) Proportion of total HLA-associated sites at which mutations were observed in Gag subunits in all
subjects.
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 numbers of HLA-associated polymorphisms identiﬁed. A high
proportion of allele-speciﬁc mutations were observed in EC
regardless of the HLA class I allele type in both the Gag and
Nef proteins (Fig. 2). Of importance, for the majority of the
alleles, EC viruses carried numbers of allele-speciﬁc mutations
comparable to those of CP viruses. However, a signiﬁcantly
lower proportion of HLA-associated polymorphisms was ob-
served in EC compared to CP for certain alleles, including
HLA-A03, A30, B15, B27, Cw06, and Cw07 in Gag and for
HLA-B57, Cw07, and Cw12 in Nef (Fig. 2A to F).
We next repeated this analysis for HLA-B57, which is over-
represented in EC and is associated with a large number of
HLA allele-speciﬁc polymorphisms (28), allowing sufﬁcient
numbers to evaluate mutations inside and outside of epitopes
separately (Fig. 3). B57 EC viruses tended to encode a smaller
proportion of B57-associated changes inside predicted CTL
epitopes in Gag than did B57 CP viruses; however, the differ-
ence did not reach statistical signiﬁcance (P  0.0569) (Fig.
3A). Such a trend was not seen for the Nef protein (P 
0.3046). As suggested by our earlier analyses, we observed
signiﬁcant differences in the frequency of B57-associated poly-
morphisms occurring outside of predicted CTL epitopes be-
tween EC and CP for both Gag and Nef (P  0.0029 and P 
0.0355, respectively, Fig. 3B). Assuming that B57-associated
changes outside of predicted CTL epitopes represent com-
pensatory mutations, these data further indicate that the
frequency of compensatory mutations may help to explain
signiﬁcant differences in the clinical disease course between
B57 EC and B57 CP and may help explain why simple
within-epitope sequence analysis has not shown any associ-
ation (24). This model is consistent with recent results dem-
onstrating the impact of escape and compensation on viral
FIG. 2. Proportions of HLA-associated mutations in the Gag and Nef proteins by individual HLA class I alleles. The mean and standard error
of the proportion of sites with deﬁned HLA-associated polymorphisms at which mutations were observed are shown. HLA class I alleles present
in more than four EC are shown. (A) HLA-A-associated mutations in the Gag protein. (B) HLA-B-associated mutations in the Gag protein.
(C) HLA-C-associated mutations in the Gag protein. (D) HLA-A-associated mutations in the Nef protein. (E) HLA-B-associated mutations in the
Nef protein. (F) HLA-C-associated mutations in the Nef protein.
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 replication capacity for the HLA-B57-restricted Gag epitope
TW10 (6).
These results add considerably to currently available data (2,
4) in that they are based upon a substantially larger number of
EC viral sequences and include multiple coding regions, they
assess putative escape from CTLs in the context of multiple
HLA class I alleles, they make direct comparison to CP viruses,
and they use EC plasma viral sequences rather than proviral
sequences, the latter of which do not represent actively repli-
cating viruses in vivo in EC.
Why is it that escape from CTLs occurs in the context of
such profound control of viremia? There are several feasible
explanations. Firstly, CTLs targeting epitopes without escape
may be contributing to the prevention of breakthrough viremia
in EC. A few studies have suggested that subdominant CTL
responses have an important role in controlling viremia (12,
13). Secondly, impaired viral pathogenicity due to CTL escape
mutations may play a major role in controlling viremia. Recent
studies demonstrating reduced viral replication capacity by
HLA-B57 CTL escape mutations and recovery by putative
compensatory mutations that occur outside of epitopes sup-
port this explanation (6, 22). As expected, we saw a stronger
difference in the number of B57-associated mutations outside
of predicted HLA-B57 epitopes than inside them. The role of
compensatory mutations in HIV-1 disease progression remains
unclear in non-B57 subjects. However, we also observed
greater differences between EC and CP in the proportion of
HLA-associated changes outside of CTL epitopes rather than
within epitopes in B57-negative subjects (data not shown),
suggesting that this mechanism might be applied to patterns of
escape and disease progression for non-B57 alleles. Thirdly, de
novo CTL responses targeting escape variants may contribute
to the prevention of breakthrough viremia. Recognition of
escape variants by HIV-speciﬁc CTLs has been reported (4,
11), yet the association with disease outcome is unknown.
Finally, as observed in a different cohort in which individuals
who subsequently achieved a low virus set point had experi-
enced high viremia during the acute phase (our unpublished
data), there is the possibility that a certain level of escape from
CTLs is introduced during acute/early infection regardless of
the subsequent viral set point. Similarly, there might be a
concern that a longer duration of infection in EC than in CP
increased the chance of viral evolution in EC regardless of the
cause of viremia control. However, the important ﬁnding here
is that, despite frequent evidence of escape from CTLs, viremia
is still under control in EC. This suggests that escape per se is
not necessarily detrimental, perhaps because of ﬁtness con-
straints imposed.
There are limitations to the present study. HLA-associated
polymorphisms outside of predicted CTL epitopes may repre-
sent false-positive associations, peptide processing mutations,
or escape mutations in as-yet-undeﬁned epitopes, so it will be
important to investigate these mutations with larger cohorts
and improved approaches to differentiate compensatory mu-
tations from CTL escape mutations. Another limitation is that
the list of HLA-associated polymorphisms used here was gen-
erated based upon viral sequences derived from chronic pro-
gressive infection and may have missed unique escape muta-
tions present only in EC, if such mutations occur. Finally, the
allele-speciﬁc mutations observed here are interpreted to be
escape from CTLs, yet this has not been shown experimentally.
Indeed, current assays using synthetic peptides to sensitize
target cells in order to evaluate escape from CTLs are of
limited value, since they do not assess potential impacts on
antigen processing and presentation. Since these HLA allele-
speciﬁc mutations are observed in plasma virus, the most likely
interpretation is that they represent escape, but infection of
cells with mutated viruses will be required to fully resolve this
issue.
In conclusion, despite viral loads of 50 RNA copies/ml, EC
plasma viruses display a substantial number of HLA-associated
polymorphisms regardless of HLA class I allele types, indicat-
ing that viral escape from HIV-speciﬁc CTLs is common in EC.
Further studies will be important to reveal the mechanisms of
viremia control despite apparent escape from CTLs in persons
who are able to maintain durable control of HIV infection.
FIG. 3. Comparison of proportions of B*57-associated mutations
between EC and CP. The mean and standard error of the proportion
of HLA-associated sites at which mutations were observed are shown.
(A) Proportion of B*57-associated sites falling within predicted B*57
CTL epitopes (inside epitopes and  3 aa) at which mutations were
observed in the Gag and Nef proteins. (B) Proportion of B*57-asso-
ciated sites outside of predicted B*57 CTL epitopes (outside of pre-
dicted epitopes and 3 aa) at which mutations were observed in the
Gag and Nef proteins.
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AUTHOR’S CORRECTION
HLA-Associated Viral Mutations Are Common in Human
Immunodeﬁciency Virus Type 1 Elite Controllers
Toshiyuki Miura, Chanson J. Brumme, Mark A. Brockman, Zabrina L. Brumme,
Florencia Pereyra, Brian L. Block, Alicja Trocha, Mina John, Simon Mallal,
P. Richard Harrigan, and Bruce D. Walker
Ragon Institute (formerly Partners AIDS Research Center), Massachusetts General Hospital, Charlestown, Massachusetts 02129;
Division of AIDS, Harvard Medical School, Boston, Massachusetts 02115; Howard Hughes Medical Institute, Chevy Chase,
Maryland 20815; Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University,
Perth, Australia; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada; and
Division of AIDS, Faculty of Medicine, University of British Columbia,
Vancouver, British Columbia, Canada
Volume 83, no. 7, p. 3407–3412, 2009. GenBank accession numbers were erroneously omitted from the original publication. The
GenBank accession numbers for the sequences derived from HIV elite controllers are EU517762 through EU517815 and
EU517972 through EU518012 (as described in reference 25 of the original manuscript), EU873003 and EU873005 (as described
in reference 26 of the original manuscript), and GU046566 through GU046604. The majority of the GenBank accession numbers
for the sequences used to create the map of HLA-associated mutations appeared in references 7 and 9 of the original manuscript,
and additional GenBank accession numbers are GQ303719 through GQ304249, GQ371216 through GQ372824, GQ398382
through GQ398387, and AY856956 through AY857186 (as described in a new publication [1]).
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Frahm, C. Brander, D. W. Haas, S. A. Riddler, R. Haubrich, B. D. Walker,
P. R. Harrigan, D. Heckerman, and S. Mallal. 19 August 2009, posting date.
HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and
Nef proteins. PLoS One 4:e6687.
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